The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CGON | +42.37% | N/A | N/A | +8% |
| S&P | +15.66% | +86.6% | +13.29% | +41% |
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul DeRidder on September 24, 2010 and is headquartered in Irvine, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.67M | 3774.4% |
| Gross Profit | -$327.00K | -1586.4% |
| Gross Margin | -19.63% | -70.8% |
| Market Cap | $3.07B | 21.4% |
| Market Cap / Employee | $27.18M | 0.0% |
| Employees | 113 | 85.2% |
| Net Income | -$43,808.00K | -114.7% |
| EBITDA | -$50,713.00K | -79.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $45.15M | 4.0% |
| Accounts Receivable | $515.00K | 0.0% |
| Inventory | 1.5 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.33M | 8814.1% |
| Short Term Debt | $912.00K | 305.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.63% | 0.0% |
| Return On Invested Capital | -22.35% | 3.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$38,991.00K | -144.9% |
| Operating Free Cash Flow | -$38,894.00K | -144.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.61 | 2.54 | 2.81 | 4.58 | 0.60% |
| Price to Sales | 1917.58 | 2818.48 | 3596.91 | 1421.65 | -66.16% |
| Price to Tangible Book Value | 3.61 | 2.54 | 2.81 | 4.58 | 0.60% |
| Enterprise Value to EBITDA | -37.91 | -27.94 | -27.21 | -47.67 | -42.22% |
| Return on Equity | -19.2% | -16.6% | -21.0% | -24.7% | - |
| Total Debt | $238.00K | $1.04M | $994.00K | $7.24M | 2346.28% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
